HCPCS Level II code J7345 identifies aminolevulinic acid HCl 10% gel, 10 mg, a topical dermatologic pharmaceutical used in clinician-administered skin treatments. This code matters nationally because it standardizes reporting and billing for a distinct topical drug formulation that is used in procedural dermatology and related outpatient services. Accurate coding affects payer coverage determinations, claims processing, and aggregated utilization reporting across health systems.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for the medication, the typical service and site of service, and the implications for billing workflows. The publication highlights common modifiers associated with drug and service claims, notes the absence of payer-specific contractual details in the input, and outlines what types of benchmarks and policy updates would typically be relevant for this HCPCS Level II code.

This summary equips billing managers, dermatology clinicians, and policy stakeholders with the essential context to understand how J7345 is used in practice, what payers are typically involved at the national level, and what documentation and coding areas to review when this topical pharmaceutical is administered in outpatient settings.